Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A

SSSE:600436
130.88
CNY
+0.75
(+0.58%)
2.09EPS
54.08P/E
71.19BMarket Cap
Apr 12Next Earn

Total Valuation

CNY

As of September 30, 2026, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A carries a market capitalization of 71.19B, placing it among publicly traded companies globally. Its enterprise value stands at 70.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap71.19B
Enterprise Value70.50B

Important Dates

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for April 12, 2027.

Earnings Date4/12/2027

Share Statistics

As of September 30, 2026, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A has 603.32M shares outstanding.

Shares Outstanding603.32M

Valuation Ratios

As of September 30, 2026, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 54.08. The price-to-sales ratio is 9.01, and the price-to-book ratio stands at 5.03.

PE Ratio54.08
PS Ratio9.01
PB Ratio5.03
P/TBV Ratio5.16

Enterprise Valuation

As of September 30, 2026, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 46.69 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 8.91 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 46.69 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 70.50B versus a market cap of 71.19B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales8.91
EV / EBITDA46.69
EV / EBIT46.69

Financial Position

As of September 30, 2026, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A maintains a current ratio of 4.92, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.97, indicating elevated leverage, while an interest coverage ratio of 51.43 demonstrates strong ability to service its debt obligations.

Current Ratio4.92
Quick Ratio0.81
Debt / Equity6.97
Debt / EBITDA0.68
Interest Coverage51.43

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 2.74M in revenue per employee across its workforce of 2,886.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee2.74M
Employee Count2,886.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A recorded 244.39M in income tax expense. That works out to an effective tax rate of 16.23, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.51B, leaving 1.32B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax244.39M
Effective Tax Rate16.23

Stock Price Statistics

CNY

As of the close on November 17, 2026, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A's stock has declined approximately 26.87% over the past 52 weeks. The 50-day moving average sits at 124.03, while the 200-day moving average is 136.00.

52-Week Price Change-26.87%
50-Day Moving Average124.03
200-Day Moving Average136.00

Income Statement

CNY

Over the twelve months ended September 30, 2026, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A generated 7.91B in revenue and converted that into 1.32B in net income, yielding earnings per share of 2.09. EBITDA reached 1.51B, while operating income came in at 1.56B.

Revenue7.91B
Gross Profit2.79B
Operating Income1.56B
Pretax Income1.51B
Net Income1.32B
EBITDA1.51B
EBIT1.51B
Earnings Per Share (EPS)2.09

Balance Sheet

CNY

As of September 30, 2026, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A holds 2.23B in cash and equivalents against 1.02B in total debt, resulting in a net debt position of -1.36B. Total book value stands at 14.15B, with working capital of 10.74B providing operational flexibility.

Cash & Cash Equivalents2.23B
Total Debt1.02B
Net Debt-1.36B
Equity (Book Value)14.15B
Book Value Per Share23.46
Working Capital10.74B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-586.64M

Margins

Over the twelve months ended September 30, 2026, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A posted a gross margin of 35.26, reflecting its pricing power and cost economics. The operating margin of 19.70 and net profit margin of 16.65 provide insight into operational efficiency.

Gross Margin35.26
Operating Margin19.70
Pretax Margin19.05
Profit Margin16.65
EBITDA Margin19.09

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A paid dividends of 1.60 per share. The dividend payout ratio of 80.26 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.45, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share1.60
Payout Ratio80.26
Shareholder Yield1.45

Stock Splits

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A's most recent stock split took place on May 24, 2016 with a 2:3 split ratio.

Last Split Date5/24/2016
Split Ratio2:3

Scores

As of September 30, 2026, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 16.31, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score16.31